DDInter1668 DDInter1147
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Siltuximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Siltuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Propafenone
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Siltuximab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Propafenone
Siltuximab may lead to a major life threatening interaction when taken with Etanercept
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib